Kolinpharma, a company listed on AIM Italia and active in nutraceuticals (merger of the terms "nutrition" and "pharmaceutical"), closed the first half-year with revenues almost doubled, from 1,4 to 2,7 million euros (+98% ), while the total number of prescriptions grew by 49% compared to the same period of the previous year for a total of 180.836 (121.319 in 2017).
As at 30 June 2018, there were 67 Medical and Scientific Representatives of the company; therefore the strategy of strengthening the growing network continues compared to 37 scientific representatives as at 31 December 2017 and 63 in the first quarter of 2018.
“We are extremely satisfied with the results achieved in this first half year which demonstrate how our growth and development path pursued is bringing tangible results – commented the CEO Emanuele Lusenti – The double-digit growth of all the main economic indicators is also the further confirmation of the great potential of the reference market in which we operate and which we always want to oversee with greater effectiveness".
Today, Kolinpharma's share on the Stock Exchange gains 2,35%, to 6,85 euros.
